ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/01/201613:50:00Pershing Square Lays Off Eight Lower-Level Employees
07/01/201607:40:00AstraZeneca Ends European Licensing Pact With Valeant
07/01/201606:28:00AstraZeneca Ends European Pact for New Skin Drug with Valeant...
07/01/201603:03:00AstraZeneca Licenses Drugs to LEO Pharma, Ends Valeant License
07/01/201602:00:00Valeant Pharmaceuticals Announces New Licensing Arrangement For...
07/01/201602:00:00Valeant Pharmaceuticals Announces New Licensing Arrangement For...
06/27/201615:42:12Statement of Changes in Beneficial Ownership (4)
06/27/201608:00:00Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand...
06/27/201608:00:00Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand...
06/21/201619:49:50Statement of Changes in Beneficial Ownership (4)
06/21/201619:31:17Initial Statement of Beneficial Ownership (3)
06/21/201619:23:54Initial Statement of Beneficial Ownership (3)
06/21/201619:16:38Initial Statement of Beneficial Ownership (3)
06/21/201617:03:52Current Report Filing (8-k)
06/17/201608:00:00Valeant Pharmaceuticals Announces Significant Investments In...
06/17/201608:00:00Valeant Pharmaceuticals Announces Significant Investments In...
06/16/201608:00:00Valeant Pharmaceuticals Announces Launch Of New PreserVision®...
06/16/201608:00:00Valeant Pharmaceuticals Announces Launch Of New PreserVision®...
06/15/201615:49:20Current Report Filing (8-k)
06/15/201608:00:00Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad